Monday June 21, 1999

COMPANY PRESS RELEASE

Transgenomic Opens Two New Offices In Support of Rapidly Growing Technology

Transgenomic, Inc. has opened offices in Cambridge, MA, a suburb of Boston and Gaithersburg, MD, a suburb of Washington, DC. These new locations will serve as sales and technical support offices for the Company.

"I am pleased to announce the opening of these new offices, and more so, to be able to announce that we have staffed the offices with the highest quality people", said Collin D'Silva, CEO. Chris Hanna, Ph.D. and Fred Wingerath are located in Cambridge, while Michael Marino, Ph.D., Michael Bedford, Ph.D. and Joseph Devaney, Ph.D. work from the Gaithersburg office. "Each of the new offices has a lab and is set up with a WAVE® Nucleic Acid Analysis System, so that demonstrations of the technology can be facilitated to existing customers, as well as the large potential customer base. We also have a growing list of collaborative efforts with National Cancer Institute, US Department of Agriculture, Cornell University and leaders in the use of DNA fingerprinting for forensic applications," said D'Silva. "These facilities fit nicely with our mission of being a leader in the rapidly growing Life Science arena," D’Silva went on to say.

Transgenomic, Inc. markets the WAVE® Nucleic Acid Analysis System, which incorporates patented technology for the automated separation and analysis of DNA. The Company believes the technology offers significant advances in speed and information gathering ability over existing technologies.

Certain statements made by Transgenomic, Inc. in this press release may be forward looking. These may be identified by the use of forward-looking words or phrases such as in the following examples: "anticipate," "believe," "estimated," "think," "planned," "potential," "should," others. Any forward-looking statements are based on the Company's current expectations. The Company undertakes no obligation to publicly release the results of any revisions to any forward looking statement, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Statements in this release should be evaluated in light of these important factors.

For more information contact investorrelations@transgenomic.com.